CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2023	$ 245,906	$ 41	$ 400,172	$ 141	$ (154,448)
Beginning balance, shares at Dec. 31, 2023		41,292,027
Exercise of common stock options	3,631	$ 1	3,630
Exercise of common stock options, shares		688,596
Vesting of restricted stock units		22,360
Vesting of restricted stock awards and stock options	273		273
Issuance of common stock under the Employee Stock Purchase Plan	651		651
Issuance of common stock under the Employee Stock Purchase Plan, shares		49,722
Issuance of common stock and pre-funded warrants in the Private Placement, net of issuance costs	89,695	$ 6	89,689
Issuance of common stock and pre-funded warrants in the Private Placement, net of issuance costs, shares		5,357,144
Issuance of common stock under the Sales Agreement, net of issuance costs	38,625	$ 1	38,624
Issuance of common stock under the Sales Agreement, net of issuance costs, shares		1,526,610
Stock-based compensation	20,174		20,174
Net loss	(89,024)				(89,024)
Other comprehensive income (loss)	(86)			(86)
Ending balance at Dec. 31, 2024	309,845	$ 49	553,213	55	(243,472)
Ending balance, shares at Dec. 31, 2024		48,936,459
Exercise of common stock options	2,295	$ 0	2,295
Exercise of common stock options, shares		516,013
Vesting of restricted stock units		30,172
Vesting of restricted stock awards and stock options	67		67
Issuance of common stock under the Employee Stock Purchase Plan	620		620
Issuance of common stock under the Employee Stock Purchase Plan, shares		36,414
Issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs	216,169	$ 10	216,159
Issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs, shares		9,920,987
Stock-based compensation	34,019		34,019
Net loss	(103,694)				(103,694)
Other comprehensive income (loss)	279			279
Ending balance at Dec. 31, 2025	$ 459,600	$ 59	$ 806,373	$ 334	$ (347,166)
Ending balance, shares at Dec. 31, 2025		59,440,045

Enliven Therapeutics, Inc. 10-K